Clinical trial
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
NCT02168829 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- August 14, 2025
- Enrollment
- 1,284 (actual)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.